Literature DB >> 20922462

The guardians of the genome (p53, TA-p73, and TA-p63) are regulators of tumor suppressor miRNAs network.

Lakshmanane Boominathan1.   

Abstract

The tumor suppressor p53 homologues, TA-p73, and p63 have been shown to function as tumor suppressors. However, how they function as tumor suppressors remains elusive. Here, I propose a number of tumor suppressor pathways that illustrate how the TA-p73 and p63 could function as negative regulators of invasion, metastasis, and cancer stem cells (CSCs) proliferation. Furthermore, I provide molecular insights into how TA-p73 and p63 could function as tumor suppressors. Remarkably, the guardians--p53, p73, and p63--of the genome are in control of most of the known tumor suppressor miRNAs, tumor suppressor genes, and metastasis suppressors by suppressing c-myc through miR-145/let-7/miR-34/TRIM32/PTEN/FBXW7. In particular, p53 and TA-p73/p63 appear to upregulate the expression of (1) tumor suppressor miRNAs, such as let-7, miR-34, miR-15/16a, miR-145, miR-29, miR-26, miR-30, and miR-146a; (2) tumor suppressor genes, such as PTEN, RBs, CDKN1a/b/c, and CDKN2a/b/c/d; (3) metastasis suppressors, such as Raf kinase inhibitory protein, CycG2, and DEC2, and thereby they enlarge their tumor suppressor network to inhibit tumorigenesis, invasion, angiogenesis, migration, metastasis, and CSCs proliferation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20922462     DOI: 10.1007/s10555-010-9257-9

Source DB:  PubMed          Journal:  Cancer Metastasis Rev        ISSN: 0167-7659            Impact factor:   9.264


  60 in total

1.  MicroRNA profiling identifies miR-29 as a regulator of disease-associated pathways in experimental biliary atresia.

Authors:  Nicholas J Hand; Amber M Horner; Zankhana R Master; LaTasha A Boateng; Claire LeGuen; Marina Uvaydova; Joshua R Friedman
Journal:  J Pediatr Gastroenterol Nutr       Date:  2012-02       Impact factor: 2.839

Review 2.  Role of the nucleus in apoptosis: signaling and execution.

Authors:  Evgeniia A Prokhorova; Alexey V Zamaraev; Gelina S Kopeina; Boris Zhivotovsky; Inna N Lavrik
Journal:  Cell Mol Life Sci       Date:  2015-09-07       Impact factor: 9.261

Review 3.  p53, a translational regulator: contribution to its tumour-suppressor activity.

Authors:  V Marcel; F Catez; J-J Diaz
Journal:  Oncogene       Date:  2015-03-02       Impact factor: 9.867

Review 4.  Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies.

Authors:  Zijun Y Xu-Monette; L Jeffrey Medeiros; Yong Li; Robert Z Orlowski; Michael Andreeff; Carlos E Bueso-Ramos; Timothy C Greiner; Timothy J McDonnell; Ken H Young
Journal:  Blood       Date:  2012-01-24       Impact factor: 22.113

5.  A p53 axis regulates B cell receptor-triggered, innate immune system-driven B cell clonal expansion.

Authors:  Hyunjoo Lee; Shabirul Haque; Jennifer Nieto; Joshua Trott; John K Inman; Steven McCormick; Nicholas Chiorazzi; Patricia K A Mongini
Journal:  J Immunol       Date:  2012-05-18       Impact factor: 5.422

6.  Aberrant activation of p53 due to loss of MDM2 or MDMX causes early lens dysmorphogenesis.

Authors:  Yiwei Zhang; Xin Zhang; Hua Lu
Journal:  Dev Biol       Date:  2014-09-28       Impact factor: 3.582

Review 7.  Are microRNAs the Molecular Link Between Metabolic Syndrome and Alzheimer's Disease?

Authors:  Juan F Codocedo; Juvenal A Ríos; Juan A Godoy; Nibaldo C Inestrosa
Journal:  Mol Neurobiol       Date:  2015-05-15       Impact factor: 5.590

8.  Non-coding RNAs in DNA damage response.

Authors:  Yunhua Liu; Xiongbin Lu
Journal:  Am J Cancer Res       Date:  2012-11-20       Impact factor: 6.166

Review 9.  Aberrant expression of microRNAs in bladder cancer.

Authors:  Hirofumi Yoshino; Naohiko Seki; Toshihiko Itesako; Takeshi Chiyomaru; Masayuki Nakagawa; Hideki Enokida
Journal:  Nat Rev Urol       Date:  2013-05-28       Impact factor: 14.432

10.  Clinical and prognostic significance of miR-155 and miR-146a expression levels in formalin-fixed/paraffin-embedded tissue of patients with diffuse large B-cell lymphoma.

Authors:  Hua Zhong; Lan Xu; Ji-Hua Zhong; Fei Xiao; Qiang Liu; Hong-Hui Huang; Fang-Yuan Chen
Journal:  Exp Ther Med       Date:  2012-03-02       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.